

1 **Methods**

2

3 **Animals**

4 NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory, Bar
5 Harbour, ME, USA) were used in this study. 0.5×10^6 primary AML blasts or MV411
6 AML cells were intravenously injected into non-irradiated NSG mice. Mice were
7 monitored by *in vivo* bioluminescent imaging (Bruker, Coventry UK). Animals were
8 housed in a specific pathogen-free facility. All animal work used in this study were
9 carried out in accordance with regulations set by the UK Home Office and the Animal
10 Scientific Procedures Act 1986. Mice used were at age 8-12 weeks of age and both
11 genders were used for experiments.

12

13 **Method Details**

14

15 **Primary cell isolation and culture**

16 Primary AML blasts were obtained from the bone marrow of AML patients with
17 informed consent, under approval from the UK National Research Ethics Service
18 (LRCEref07/H0310/146). Non-malignant CD34+ haematopoietic stem cells were
19 obtained from cord blood from caesarean section. AML cell isolation was carried out
20 by gradient density centrifugation using Histopaque (Sigma-Aldrich) and cell type was
21 confirmed by flow cytometry as previously described (1). CD34+ HSC were first
22 isolated using gradient density centrifugation followed by CD34+ microbeads
23 magnetic separation (Miltenyi Biotec). Mesenchymal stromal cell (MSC) were isolated
24 by gradient density centrifugation and characterized by their fibroblast like shape and
25 adherence to tissue culture plastic. MSC were expanded in Dulbecco's Modified
26 Eagle's Medium (DMEM) supplemented with 20% foetal bovine serum (FBS) and 1%
27 penicillin-streptomycin (Hyclone, Life Sciences). MSC were further characterised
28 using flow cytometry for expression of CD90+, CD73+, CD105+ and CD45-.

29

30 **Flow Cytometry**

31 In this study the CyFlow Cube 6 (Sysmex, Milton Keynes, UK) was used. Cells were
32 incubated for 5 minutes with an FCR receptor blocker (Miltenyi Biotec,) and then
33 stained with isotype controls or test antibodies human CD38-FITC (Miltenyi Biotec).
34 For experiments using BCL-2-FITC the cells fixed and permeabilized using the FIX &

35 PERM™ Cell Permeabilization Kit (ThermoFisher) as per manufacturer's instructions.
36 The cells were then stained with BCL-2FITC, human and mouse (Miltenyi Biotec) for
37 20 minutes centrifuged at 1200rpm for 5 minutes before resuspending in PBS. Data
38 were analyzed using FlowJo (TreeSta). See figures for specific gating strategies.

39

40 **Annexin V assay**

41 MSC were seeded at 5×10^4 cells/well of a 24-well plate AML cells were placed on the
42 MSC at a density of 1.5×10^5 in normal growth media. Control PBS, Venetoclax
43 (100nm) alone Daratumumab (100ng/ml) alone or Venetoclax and Daratumumab in
44 combination were then added to the coculture. MSC/AML cocultures were then
45 incubated for 24 hours. AML blasts were removed, and apoptosis was quantified using
46 PI/AnnexinV assay (eBiosciences) and annexin V positive cells were measured using
47 flow cytometry.

48

49 **Cell titre glow**

50 The viability of AML following culture with Daratumumab or Venetoclax was assessed
51 using the CellTitre-Glo assay (Promeg). For the assay 1×10^4 primary AML cells in $50 \mu\text{l}$
52 were cultured in a 96 well plate and cultured with varying does of Daratumumab or
53 Venetoclax or Venetoclax and Daratumumab in combination for 24hours. The cells
54 were then transferred to a 96 well white plate and $50 \mu\text{l}$ of CellTitre-Glo substrate was
55 added and incubated for 10 minutes in the dark. Luminecence was measured at an
56 emission wavelength 560nm using the LUMIstar Omega microplate reader (BMG
57 LABTECH).

58

59 **Bioluminescence imaging**

60 To monitor AML engraftment bioluminescent imaging of live mice was carried out.
61 Mice were intraperitoneally injected with 150mg/kg D-luciferin on day 7 and 17. The
62 mice were then left for 15 minutes at room temperature for maximum detection of the
63 luciferase signal. The mice anaesthetised using a chamber filled with isoflurane. The
64 mice were an imaged using a pre-set method of 1-minute exposure bioluminescent
65 image, x-ray and light image.

66

67

68

69 **Quantification and Statistical Analysis**

70 Due to variability in the data, statistical comparison of work was performed without
71 assumption of normal distribution using Mann-Whitney U test. For statistical
72 comparison of more than two groups were compared, Kruskal-Wallis test followed by
73 Dunn's multiple comparisons using Prism version 7.00 for Windows (GraphPad).
74 Differences among group means were considered significant when the probability
75 value, p, was less than 0.05* 0.01**. Sample size (n) represents number of biological
76 replicates. No statistical methods were used to predetermine sample size.

77

78

79

80 **References**

81 1. Zaitseva L, Murray MY, Shafat MS, Lawes MJ, MacEwan DJ, Bowles KM, et
82 al. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. *Oncotarget*.
83 2014;5(20):9930-8.

84